VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2021 | RV-471: novel PROTAC® estrogen receptor degrader, in ER+ breast cancer

Erika Hamilton, MD, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, discusses the safety results of the first-in-human study of ARV-471, a novel PROTAC® estrogen receptor degrader. ARV-471 was found to be well tolerated with no dose-limiting toxicities. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter